AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

NCT ID: NCT03192215

Last Updated: 2025-04-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1015 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-19

Study Completion Date

2023-04-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives

* Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
* Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at up to 200 sites in and out of the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 7 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Active treatment will be either apixaban 5 mg or aspirin 81 mg. An adjusted dose of apixaban 2.5 mg will be used for subjects with at least two of the following: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or known serum creatinine greater than or equal to 1.5 mg/dL. There will be six possible study tablets: apixaban 5 mg (regular dose), apixaban 2.5 mg (adjusted dose), apixaban 5 mg placebo, apixaban 2.5 mg placebo, aspirin 81 mg, and aspirin placebo.

All subjects will be randomized to receive active treatment with either active apixaban or active aspirin. Study treatments will be supplied in a double-dummy fashion as apixaban 5 mg (2.5 mg for the adjusted dose) or matching placebo, and aspirin 81 mg or matching placebo.
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Eligible patients will be allocated in a 1:1 ratio to apixaban or aspirin using the minimal sufficient balance randomization method to prevent serious treatment imbalances by study site.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active agent: Apixaban

Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban

Group Type EXPERIMENTAL

Apixaban

Intervention Type DRUG

5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).

Active control: Aspirin

Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin

Group Type ACTIVE_COMPARATOR

Aspirin

Intervention Type DRUG

Aspirin 81 mg by mouth once daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apixaban

5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).

Intervention Type DRUG

Aspirin

Aspirin 81 mg by mouth once daily.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Eliquis Aspirin Tablet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 45 years.
* Clinical diagnosis of ischemic stroke + brain imaging to rule out hemorrhagic stroke.
* Modified Rankin Scale (MRS) score ≤ 4.
* Ability to be randomized within 3 to 180 days after stroke onset.
* ESUS, defined as all of the following:

* Stroke detected by CT or MRI that is not lacunar. Lacunar is defined as a subcortical (this includes pons and midbrain) infarct in the distribution of the small, penetrating cerebral arteries whose largest dimension is ≤1.5 cm on CT or ≤2.0 cm on MRI diffusion images/\<1.5 cm on T2 weighted MR images. The following are not considered lacunes: multiple simultaneous small deep infarcts, lateral medullary infarcts, and cerebellar infarcts. Patients with a clinical lacunar stroke syndrome and no infarct on imaging are excluded.
* Absence of extracranial or intracranial atherosclerosis causing ≥50 percent luminal stenosis of the artery supplying the area of ischemia. Patients must undergo vascular imaging of the extracranial and intracranial vessels using either catheter angiography, CT angiogram (CTA), MR angiogram (MRA), or ultrasound, as considered appropriate by the treating physician and local principal investigator.
* No major-risk cardioembolic source of embolism, including intracardiac thrombus, mechanical prosthetic cardiac valve, atrial myxoma or other cardiac tumors, moderate or severe mitral stenosis, myocardial infarction within the last 4 weeks, left ventricular ejection fraction \<30 percent, valvular vegetations, or infective endocarditis). Patent foramen ovale is not an exclusion. All patients must undergo electrocardiogram, transthoracic or transesophageal echocardiography (TTE or TEE) and at least 24 hours of cardiac rhythm monitoring (Holter monitor or telemetry or equivalent). Additional cardiac imaging, such as cardiac MRI, or cardiac CT will be performed at the discretion of the local treating physician and principal investigator. Additional cardiac rhythm monitoring, such as monitored cardiac outpatient telemetry (MCOT) or an implanted cardiac monitor, will be at the discretion of the treating physician and local principal investigator.
* No other specific cause of stroke identified, such as arteritis, dissection, migraine, vasospasm, drug abuse, or hypercoagulability. Special testing, such as toxicological screens, serological testing for syphilis, and tests for hypercoagulability, will be performed at the discretion of the treating physician and local principal investigator.

Exclusion Criteria

* History of atrial fibrillation (AF), AF on 12-lead ECG, or any AF of any duration during heart-rhythm monitoring prior to randomization.
* Clear indication for treatment-dose anticoagulant therapy, such as venous thromboembolism or a mechanical heart valve.
* Need for antiplatelet agent, such as aspirin or clopidogrel
* History of spontaneous intracranial hemorrhage.
* Chronic kidney disease with serum creatinine ≥2.5 mg/dL.For Canadian sites only, estimated creatinine clearance (eCrCl) \<15 mL/min is also an exclusion criterion.
* Active hepatitis or hepatic insufficiency with Child-Pugh score B or C.
* Clinically significant bleeding diathesis.
* Unresolved anemia (hemoglobin \<9 g/dL) or thrombocytopenia (\<100 x 10E9/L).
* Clinically significant gastrointestinal bleeding within the past year (e.g., not due to external hemorrhoids).
* At risk for pregnancy: premenopausal or postmenopausal woman within 12 months of last menses without a negative pregnancy test or not committing to adequate birth control, which includes an oral contraceptive, two methods of barrier birth control such as condom with or without spermicidal lubricant + diaphragm, or abstinence.
* Known allergy or intolerance to aspirin or apixaban.
* Concomitant participation in another clinical trial involving a drug or acute stroke intervention.
* Considered by the investigator to have a condition that precludes follow-up or safe participation in the trial.
* Inability of either participant or surrogate to provide written, informed consent for trial participation.


Atrial cardiopathy is defined as ≥1 of the following:

* PTFV1 \>5,000 μV\*ms on 12-lead ECG (ECG criterion).
* Serum NT-proBNP \>250 pg/mL (NT-proBNP criterion).
* Left atrial diameter index ≥3 cm/m2 on echocardiogram (i.e., severe left atrial enlargement) (ECHO criterion)
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

University of Cincinnati

OTHER

Sponsor Role collaborator

Medical University of South Carolina

OTHER

Sponsor Role collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role collaborator

Pfizer

INDUSTRY

Sponsor Role collaborator

Roche Pharma AG

INDUSTRY

Sponsor Role collaborator

Weill Medical College of Cornell University

OTHER

Sponsor Role collaborator

University of Washington

OTHER

Sponsor Role collaborator

Columbia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Randolph S. Marshall, MD

Elisabeth K Harris Professor of Neurology Chief, Stroke Division

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Randolph S Marshall, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama

Birmingham, Alabama, United States

Site Status

University of South Alabama University Hospital

Mobile, Alabama, United States

Site Status

Chandler Regional Medical Center Chandler, AZ

Chandler, Arizona, United States

Site Status

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

Site Status

Banner University Medical Center - Tucson

Tucson, Arizona, United States

Site Status

Mercy San Juan Medical Center (Dignity Health)

Carmichael, California, United States

Site Status

Eden Medical Center

Castro Valley, California, United States

Site Status

Rancho Los Amigos National Rehabilitation Center

Downey, California, United States

Site Status

Fountain Valley Regional Hospital and Medical Center

Fountain Valley, California, United States

Site Status

Community Regional Medical Center

Fresno, California, United States

Site Status

UCSD Health La Jolla

La Jolla, California, United States

Site Status

Sharp Grossmont Hospital

La Mesa, California, United States

Site Status

Long Beach Memorial Medical Center

Long Beach, California, United States

Site Status

Los Alamitos Medical Center

Los Alamitos, California, United States

Site Status

Kaiser Permanente

Los Angeles, California, United States

Site Status

Keck Hospital Of USC

Los Angeles, California, United States

Site Status

Los Angeles County- USC Medical Center

Los Angeles, California, United States

Site Status

VA Greater Los Angeles - West LA VA Medical Center

Los Angeles, California, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

UC Irvine Medical Center

Orange, California, United States

Site Status

Sutter Medical Center

Sacramento, California, United States

Site Status

Salinas Valley Memorial Hospital

Salinas, California, United States

Site Status

Scripps Mercy

San Diego, California, United States

Site Status

UCSD Medical Center - Hillcrest Hospital

San Diego, California, United States

Site Status

Kaiser Permanent San Diego Medical Center

San Diego, California, United States

Site Status

Sharp Memorial Hospital

San Diego, California, United States

Site Status

San Francisco General

San Francisco, California, United States

Site Status

UCSF Medical Center

San Francisco, California, United States

Site Status

Good Samaritan

San Jose, California, United States

Site Status

Stanford University Medical Center

Stanford, California, United States

Site Status

Swedish Medical Center

Englewood, Colorado, United States

Site Status

St. Mary's Medical Center

Grand Junction, Colorado, United States

Site Status

St. Vincent's Medical Center

Bridgeport, Connecticut, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

Yale New Haven Hospital

New Haven, Connecticut, United States

Site Status

Christiana Hospital

Newark, Delaware, United States

Site Status

Med-star Georgetown Univ.

Washington D.C., District of Columbia, United States

Site Status

Medstar Washington

Washington D.C., District of Columbia, United States

Site Status

Boca Raton Regional Hospital

Boca Raton, Florida, United States

Site Status

UF Health Shands

Gainesville, Florida, United States

Site Status

Baptist Medical Center Jacksonville

Jacksonville, Florida, United States

Site Status

Mayo Clinic

Jacksonville, Florida, United States

Site Status

Jackson Memorial

Miami, Florida, United States

Site Status

Univ. Miami Hospital

Miami, Florida, United States

Site Status

Baptist Hospital of Miami

Miami, Florida, United States

Site Status

Intercoastal Medical Group - Hyde Park

Sarasota, Florida, United States

Site Status

Tampa General

Tampa, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Grady Memorial

Atlanta, Georgia, United States

Site Status

The Queen's Medical Center

Honolulu, Hawaii, United States

Site Status

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status

Rush University

Chicago, Illinois, United States

Site Status

University of Illinois

Chicago, Illinois, United States

Site Status

University of Chicago Medical Center

Chicago, Illinois, United States

Site Status

OSF St. Francis Medical Center

Peoria, Illinois, United States

Site Status

Southern Illinois University Memorial Medical Center

Springfield, Illinois, United States

Site Status

St. John's Hospital (Prairie Research)

Springfield, Illinois, United States

Site Status

Central DuPage Hospital

Winfield, Illinois, United States

Site Status

Multi-Specialty - Methodist Plaza/Unity Point

Des Moines, Iowa, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

University of Kansas

Kansas City, Kansas, United States

Site Status

Baptist Health Lexington

Lexington, Kentucky, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

University of Louisville Hospital

Louisville, Kentucky, United States

Site Status

Ochsner Medical Center

New Orleans, Louisiana, United States

Site Status

Eastern Maine Medical Center

Bangor, Maine, United States

Site Status

University of Maryland Medical Center

Baltimore, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Boston Medical Center

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical

Boston, Massachusetts, United States

Site Status

Brigham & Womens Hospital

Boston, Massachusetts, United States

Site Status

Lahey Hospital & Medical Center

Burlington, Massachusetts, United States

Site Status

U Mass Memorial Medical Center

Worcester, Massachusetts, United States

Site Status

University of Michigan University Hospital

Ann Arbor, Michigan, United States

Site Status

VA Ann Arbor Healthcare System

Ann Arbor, Michigan, United States

Site Status

Detroit Receiving Hospital

Detroit, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

McLaren Flint

Flint, Michigan, United States

Site Status

Mercy Health St. Mary's

Grand Rapids, Michigan, United States

Site Status

Spectrum Health

Grand Rapids, Michigan, United States

Site Status

McLaren Macomb, Mount Clemens, MI

Mount Clemens, Michigan, United States

Site Status

McLaren Northern Michigan

Petoskey, Michigan, United States

Site Status

Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Site Status

Hennepin County

Minneapolis, Minnesota, United States

Site Status

Univ. of Minnesota

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Regions Hospital, St. Paul

Saint Paul, Minnesota, United States

Site Status

United Hospital

Saint Paul, Minnesota, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status

Cox Medical Center South

Springfield, Missouri, United States

Site Status

St. Louis University Hospital

St Louis, Missouri, United States

Site Status

Barnes Jewish Hospital

St Louis, Missouri, United States

Site Status

CHI Health Immanuel

Omaha, Nebraska, United States

Site Status

University of Nebraska

Omaha, Nebraska, United States

Site Status

Cooper University Hospital,

Camden, New Jersey, United States

Site Status

Robert Wood Johnson

New Brunswick, New Jersey, United States

Site Status

Capital Health Medical Center Hopewell

Pennington, New Jersey, United States

Site Status

Univ. New Mexico

Albuquerque, New Mexico, United States

Site Status

Kings County Hospital

Brooklyn, New York, United States

Site Status

New York Presbyterian - Brooklyn Methodist Hospital

Brooklyn, New York, United States

Site Status

Maimonides Medical Center

Brooklyn, New York, United States

Site Status

NYU Langone Hospital - Brooklyn

Brooklyn, New York, United States

Site Status

Mount Sinai Beth Israel Brooklyn

Brooklyn, New York, United States

Site Status

Buffalo General Medical Center

Buffalo, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

NYU Langone

New York, New York, United States

Site Status

Mount Sinai West

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Weill Cornell Medicine

New York, New York, United States

Site Status

Lenox Hill Hospital

New York, New York, United States

Site Status

Strong Memorial Hospital

Rochester, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Moses H. Cone Memorial Hospital

Greensboro, North Carolina, United States

Site Status

Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, United States

Site Status

Sanford Medical Center Fargo

Fargo, North Dakota, United States

Site Status

Akron General Medical Center

Akron, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Louis Stokes VA Medical Center

Cleveland, Ohio, United States

Site Status

UH Cleveland Medical Center

Cleveland, Ohio, United States

Site Status

MetroHealth Medical Center

Cleveland, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

OSU Wexner

Columbus, Ohio, United States

Site Status

Ohio Health Riverside - Riverside Methodist Hospital

Columbus, Ohio, United States

Site Status

Miami Valley Hospita

Dayton, Ohio, United States

Site Status

Mercy St Vincent Medical Center

Toledo, Ohio, United States

Site Status

OU Medical Center Oklahoma

Oklahoma City, Oklahoma, United States

Site Status

Legacy Emanuel

Portland, Oregon, United States

Site Status

Oregon Health and Sciences

Portland, Oregon, United States

Site Status

Lehigh Valley Hospital

Allentown, Pennsylvania, United States

Site Status

UPMC Altoona

Altoona, Pennsylvania, United States

Site Status

Lancaster General Hospital

Lancaster, Pennsylvania, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Temple University

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Presbyterian

Pittsburgh, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Prisma Health Richland Hospital (formerly Palmetto Health)

Columbia, South Carolina, United States

Site Status

Prisma Health Greenville Memorial Hospital

Greenville, South Carolina, United States

Site Status

Methodist University Hospital

Memphis, Tennessee, United States

Site Status

Vanderbilt

Nashville, Tennessee, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Valley Bapist

Harlingen, Texas, United States

Site Status

Baylor College College of Medicine

Houston, Texas, United States

Site Status

Houston Methodist Hospital

Houston, Texas, United States

Site Status

Memorial Hermann Texas Medical Center

Houston, Texas, United States

Site Status

Univ of Texas Health Science Center San Antonio

San Antonio, Texas, United States

Site Status

Scott & White Memorial Hospital - Temple

Temple, Texas, United States

Site Status

Memorial Hermann The Woodlands Hospital

The Woodlands, Texas, United States

Site Status

Intermountain Medical Center

Murray, Utah, United States

Site Status

Utah Valley Regional Medical Center

Provo, Utah, United States

Site Status

Univ of Utah

Salt Lake City, Utah, United States

Site Status

George E Whalen VA

Salt Lake City, Utah, United States

Site Status

UVA Medical Center

Charlottesville, Virginia, United States

Site Status

Bon Secours St. Mary's Hospital

Richmond, Virginia, United States

Site Status

Providence St. Peter Hospital

Olympia, Washington, United States

Site Status

Harborview Medical Center

Seattle, Washington, United States

Site Status

Puget Sound VA

Seattle, Washington, United States

Site Status

Swedish Medical Center - Cherry Hill Campus

Seattle, Washington, United States

Site Status

WVU Healthcare Ruby Memorial

Morgantown, West Virginia, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

Froedtert Hospital

Milwaukee, Wisconsin, United States

Site Status

University of Calgary - Foothills Medical Centre

Calgary, Alberta, Canada

Site Status

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

Neurologic Research Center

Lethbridge, Alberta, Canada

Site Status

Kelowna General Hospital

Kelowna, British Columbia, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

Brandon Regional Health Center

Brandon, Manitoba, Canada

Site Status

Hamilton General Hospital

Hamilton, Ontario, Canada

Site Status

Kingston General Hospital

Kingston, Ontario, Canada

Site Status

London Health Sciences Center

London, Ontario, Canada

Site Status

Sunnybrook Health Sciences Center

Toronto, Ontario, Canada

Site Status

Enfant-Jesus Hospital

Québec, Quebec, Canada

Site Status

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke. 2016 Mar;47(3):895-900. doi: 10.1161/STROKEAHA.115.012004. Epub 2016 Jan 19. No abstract available.

Reference Type BACKGROUND
PMID: 26786114 (View on PubMed)

Yaghi S, Kamel H, Elkind MS. Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke. Neurology. 2015 Sep 22;85(12):1078-84. doi: 10.1212/WNL.0000000000001817. Epub 2015 Jul 17.

Reference Type BACKGROUND
PMID: 26187229 (View on PubMed)

Kamel H, Okin PM, Longstreth WT Jr, Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015 May;11(3):323-31. doi: 10.2217/fca.15.22.

Reference Type BACKGROUND
PMID: 26021638 (View on PubMed)

Yaghi S, Moon YP, Mora-McLaughlin C, Willey JZ, Cheung K, Di Tullio MR, Homma S, Kamel H, Sacco RL, Elkind MS. Left atrial enlargement and stroke recurrence: the Northern Manhattan Stroke Study. Stroke. 2015 Jun;46(6):1488-93. doi: 10.1161/STROKEAHA.115.008711. Epub 2015 Apr 23.

Reference Type BACKGROUND
PMID: 25908460 (View on PubMed)

Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013 Mar;44(3):714-9. doi: 10.1161/STROKEAHA.112.675942. Epub 2013 Jan 22.

Reference Type BACKGROUND
PMID: 23339958 (View on PubMed)

Lazar RM, Howard G, Brewer MT, Cassarly C, Pauls Q, Kemp S, Tirschwell DL, Sheth KN, Wintermark M, Kamel H, Longstreth WT Jr, Elkind MSV, Broderick JP, Lansberg MG. Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA-Cognition Study. J Am Heart Assoc. 2025 Sep 16;14(18):e042147. doi: 10.1161/JAHA.125.042147. Epub 2025 Aug 22.

Reference Type DERIVED
PMID: 40847528 (View on PubMed)

Elias A, Teraoka JT, Soliman EZ, Elkind MSV, Kamel H, Kronmal RA, Longstreth WT Jr, Tirschwell DL, Di Tullio MR, Marcus GM. Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial. J Cardiovasc Electrophysiol. 2025 Jul;36(7):1487-1493. doi: 10.1111/jce.16629. Epub 2025 Apr 28.

Reference Type DERIVED
PMID: 40294164 (View on PubMed)

Navi BB, Elkind MSV, Zhang C, Tirschwell DL, Kronmal RA, Elm J, Broderick JP, Gladstone DJ, Beyeler M, Kamel H, Longstreth WT Jr. History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial. J Am Heart Assoc. 2025 May 6;14(9):e040543. doi: 10.1161/JAHA.124.040543. Epub 2025 Apr 23.

Reference Type DERIVED
PMID: 40265582 (View on PubMed)

Lansberg MG, Wintermark M, Chen H, Howard G, Cassarly C, Pauls Q, Kemp S, Harris TL, Krishnaiah B, Stanton RJ, Lyerly MJ, Miller BR, Smith EE, Tirschwell DL, Sheth KN, Kamel H, Longstreth WT Jr, Elkind MSV, Broderick JP, Lazar RM. Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Randomized Clinical Trial. JAMA Neurol. 2025 Mar 1;82(3):220-227. doi: 10.1001/jamaneurol.2024.4838.

Reference Type DERIVED
PMID: 39869342 (View on PubMed)

Navi BB, Zhang C, Miller BR, Pawar A, Cushman M, Kasner SE, Tirschwell D, Longstreth WT, Kronmal R, Elm J, Zweifler RM, Tarsia J, Broderick JP, Gladstone DJ, Beyeler M, Kamel H, Elkind MSV, Streib C. Diagnosis of Incident Cancer After Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Trial. Neurology. 2024 Nov 26;103(10):e210027. doi: 10.1212/WNL.0000000000210027. Epub 2024 Oct 31.

Reference Type DERIVED
PMID: 39481070 (View on PubMed)

Navi BB, Zhang C, Miller B, Cushman M, Kasner SE, Elkind MSV, Tirschwell DL, Longstreth WT Jr, Kronmal RA, Beyeler M, Elm J, Zweifler RM, Tarsia J, Cereda CW, Bianco G, Costamagna G, Michel P, Broderick JP, Gladstone DJ, Kamel H, Streib C. Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial. JAMA Neurol. 2024 Sep 1;81(9):958-965. doi: 10.1001/jamaneurol.2024.2404.

Reference Type DERIVED
PMID: 39133474 (View on PubMed)

Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, Aragon Garcia R, Plummer P, Sabagha N, Pauls Q, Cassarly C, Dillon CR, Di Tullio MR, Hod EA, Soliman EZ, Gladstone DJ, Healey JS, Sharma M, Chaturvedi S, Janis LS, Krishnaiah B, Nahab F, Kasner SE, Stanton RJ, Kleindorfer DO, Starr M, Winder TR, Clark WM, Miller BR, Elkind MSV; ARCADIA Investigators. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 2024 Feb 20;331(7):573-581. doi: 10.1001/jama.2023.27188.

Reference Type DERIVED
PMID: 38324415 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.nihstrokenet.org/trials/arcadia/home

NIH/NINDS StrokeNet Prevention trials website

https://youtu.be/YIneZ4n-xXE

ARCADIA Trial Video

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1U01NS095869-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

AAAR4607

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Albumin in Acute Ischemic Stroke Trial
NCT00235495 TERMINATED PHASE3